Skip to main content


Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program

Fig. 1

Normalized observed decline from baseline to week 24 across regions in placebo group. 100%, maximal decline on the scale observed across regions; 0%, minimum decline/maximum improvement observed on the scale across regions. ADAS-Cog Alzheimer’s Disease Assessment Scale—Cognitive subscale, ADCS-ADL23 Alzheimer’s Disease Cooperative Study—Activities of Daily Living, 23-item version, ADCS-CGIC Alzheimer’s Disease Cooperative Study—Clinical Global Impression of Change, MMSE Mini–Mental State Examination, NPI Neuropsychiatric Inventory

Back to article page